A-HeFT

(redirected from African-American heart failure trial)

A-HeFT

African-American heart failure trial. A randomised, double-blind, placebo-controlled study of 1,100 African-American men and women with moderate to severe congestive heart failure, categorised as New York Heart Association (NYHA) heart failure classifications III and IV. A-HeFT assessed the effects of an NO-enhancing drug, isosorbide dinatrate (BiDil). The trial was stopped early because of marked improvement in Black patients in whom it reduced mortality by 43% and hospitalisations by 39%. Isosorbide became the first heart-failure medication to specifically address endothelial dysfunction, and is the first race-based prescription drug.
References in periodicals archive ?
Inder Anand, MD will present new hospitalization data from the landmark African-American Heart Failure Trial (A-HeFT) at the 2012 American College of Cardiology Scientific Session in Chicago, Illinois on March 26, 2012.
The African-American Heart Failure Trial (A-HeFT) showed that nitrates and hydralazine improved mortality when used with ACE inhibitors and [beta]-blockers, but their value when added to traditional therapy is unknown in other racial groups.
The FDA reports the approval of BiDil was based in part on the results of the African-American Heart Failure Trial (A-HeFT).
In the study, called the African-American Heart Failure Trial, 525 African Americans with advanced heart failure received BiDil, along with standard treatment for heart failure and another 525 half received a placebo along with standard treatment.
Fixed-dose combined isosorbide dinitrate/hydralazine improves outcomes in elderly heart failure patients in the African-American Heart Failure Trial.
org is designed specifically to help explain the significant findings of the African-American Heart Failure Trial (A-HeFT) to the medical community, including providing answers to common questions about the study's unique design and its implications for future drug trials.
Organizers of the African-American Heart Failure Trial (A-HeFT) defended the design based on results from past studies, which hinted that the effects of isosorbide dinitrate and hydralazine were strongest in African Americans, and the failure of many past studies to prove the value of cardiovascular medications in African Americans.
259) Effect of Angiotensin Converting Enzyme Inhibitor or Beta-Blocker Use on the Benefit of BiDil in the African-American Heart Failure Trial
For example, the African-American Heart Failure Trial is Nitromed's clinical trial to research the effects of BiDil, a heart failure drug combining two older cardiovascular drugs, exclusively in African-American men and women.
In-Trial Economic Evaluation of a Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure: Results from the African-American Heart Failure Trial (A-HeFT)
The Genetic Risk Assessment Sub-Study of the African-American Heart Failure Trial (A-HeFT): Impact of Genetic Variation of NOS3
Full browser ?